Background {#Sec1}
==========

Artemisinin combination therapy (ACT) is used worldwide as the first-line treatment against uncomplicated falciparum malaria \[[@CR1]\]. Dihydroartemisinin-piperaquine (DHA-PPQ) is characterized by a post-treatment prophylactic effect against re-infections that is longer than artemether-lumefantrine \[[@CR2]\]. Despite the success of ACT in reducing the global burden of malaria, the emergence of resistance to artemisinin threatens its use. In Cambodia, failure of ACT is now frequently observed \[[@CR3], [@CR4]\]. The increase of treatment failures and parasite clearance times observed soon after the widespread introduction of DHA-PPQ suggests a rapid emergence of resistance to both artemisinin and piperaquine components. In Asia, treatment failures have been reported in Myanmar \[[@CR5]\]. In South America, data on (good) efficacy of DHA-PPQ is based on only one trial, conducted in Peru between 2003 and 2005 \[[@CR6]\]. In Africa, trials conducted in Burkina Faso \[[@CR7]\], Kenya \[[@CR8]\] and Angola \[[@CR9]\] showed that DHA-PPQ was highly effective, with very rare cases of recrudescence invariably within 28 days.

Case report {#Sec2}
===========

A 72-year-old Italian woman was admitted on 26 November, 2014 to the Centre for Tropical Diseases (CTD) of Negrar (Verona), for myalgias and arthralgias since 2 days, fever (up to 40 °C) and nausea since one day. She had visited Ethiopia (Omo River Valley) from 6 to 18 November 2014. She was vaccinated against yellow fever, hepatitis A and B, but had not taken any malaria chemoprophylaxis. Her travel history included Ethiopia, Niger, India, and Nambia, not South East Asia. Upon admission, her temperature was 38.3 °C, her weight 67.5 kg. Physical examination was unremarkable. The blood tests showed white blood cells (WBCs) 3.85 × 10^9^/L (normal range 5.2--12.4 × 10^9^/L), haemoglobin (Hb) 12.5 g/dL (normal range 14--18 × g/dL), platelets 46 × 10^9^/L (normal range 130--400 × 10^9^/L), C-reactive protein 135 mg/L (normal range 0--5 mg/L), procalcitonin 14 μg/L (normal range 0--0.5 μg/L). The quantitative buffy coat (QBC) test, antigen malarial test and blood smears resulted positive for *Plasmodium falciparum*, with a parasitaemia of 0.3% (14,600/μL). The patient was treated with DHA-PPQ 320/40 mg, three tablets/day for 3 days. The first day after treatment the parasitaemia dropped to 0.0023% (96/μL). After two days, the blood films and the QBC test resulted negative. Also, iv ceftriaxone 2 g/day was administrated for a left basal bronchopneumonia. The patient was discharged on 5 December, 2014.

At a follow-up visit on 23 December, the QBC test and blood smears were still negative. The blood tests showed WBC 7.98 × 10^9^/L, Hb 11.8 g/dL, platelets 233 × 10^9^/L.

She was re-admitted on 7 January, 2015 complaining of fever, nausea and vomiting that had started 7 days before (more than 4 weeks after anti-malaria treatment). The QBC test, antigen malarial test and blood smears all resulted positive again for falciparum malaria, with a parasitaemia of 0.4% (12,100/μL). WBCs were 5.5 × 10^9^/L, Hb 9.5 g/dL, platelets 96 × 10^9^/L. The patient was treated this time with atovaquone-proguanil 250/100 mg, four tablets/day for 3 days. The parasitaemia decreased to 0.36% (10,930/μL) 24 h after first dose of treatment, 0.16% (5017/μL) the second day, 0.0016% (46/μL) the third day. After 4 days, blood films resulted negative. The patient was discharged on 12 January, 2015.

At follow-up visits 28 and 56 days after the second malaria episode, QBC and blood smears resulted negative and the main laboratory findings were normal.

The malaria-PCR performed a posteriori on a blood specimen collected on 23 December, 2014 resulted positive. Serum DHA-PPQ concentrations were retrospectively evaluated on cryo-preserved (−80 °C) samples taken on different days, during and after the drug administration, coupled with tandem-mass spectrometry (Table [1](#Tab1){ref-type="table"}). Limits of quantification for DHA and PPQ were 0.31 and 12.5 ng/mL, respectively. Pharmacokinetic data after the last dose of the three-day course of DHA and PPQ were comparable to data published by Nguyen et al. \[[@CR10]\] indicating no defect in drug absorption. PPQ serum concentration on day 7 was calculated on the basis of the drug elimination half-life in this patient. Calculated PPQ concentrations on day 7 showed a serum level of 110 ng/mL (levels below 30 ng/mL have been associated to a higher risk of recurrence of malaria) \[[@CR11]\].Table 1Serum concentrations of dihydroartemisinin-piperaquinePiperaquine (ng/mL)Dihydroartemisinin (ng/nL)Hours since last administrationDay 11320.7410Day 22820.3415Day 32341.3415Day 4205N.v.39Day 5131--63Day 2818--591Day 7 (calculated)110--111

Genotyping of *P*. *falciparum* isolate(s) responsible for the patient's infection was performed by amplification of three polymorphic markers, the merozoite surface protein 1 (*msp1*), merozoite surface protein 2 (*msp2*), and glutamate-rich protein (*glurp*) genes. These genes show a length polymorphism, allowing the detection of multiple infections by different *P*. *falciparum* genotypes \[[@CR12], [@CR13]\]. Total genomic DNAs were extracted using PureLink Genomic DNA Kits-Invitrogen, from 200 µl of whole infected blood samples collected from the patient at the first (27 November, 2014) and second (7 January, 2015) hospital admittances. PCR amplified for *msp1/msp2* and for *glurp* as described by Wooden et al. \[[@CR12]\] and Viriyakosol et al. \[[@CR13]\], respectively. Genetic characterization of the *P*. *falciparum* isolates showed the presence of a single isolate responsible for the first episode and for the recurrence (Fig. [1](#Fig1){ref-type="fig"}). In order to investigate the resistance to the anti-malarial drugs of the isolate of *P. falciparum* infecting the patient, PCR amplification and sequencing were performed, in order to evaluate the presence of point mutations in the six molecular markers of *P*. *falciparum (PfK13, Pfcrt, Pfmdr1, Pfdhfr, Pfdhps* and *PfCytB* genes*)* linked to resistance to the artemisinin derivatives, quinolines, antifolates-cycloguanil and atovaquone. The polymorphism of the propeller domain of the *Pfk13* gene was assessed as described by Taylor et al. \[[@CR14]\]. Analysis of *Pfcrt*/*Pfdhps* and *Pfmdr1* and genes was performed as previously described in Menegon et al. \[[@CR15]\] and Duraisingh et al. \[[@CR16]\], respectively. A fragment of *Pfdhfr* gene spanning codons 51--108 was analysed as described by Palmieri et al. \[[@CR17]\]. The presence of point mutation in PfCytB gene was evaluated as described in Korsinczky et al. \[[@CR18]\]. All PCR products were sent to Eurofins Genomics Company (Germany) for sequencing. The obtained sequences were compiled and analysed by Accelrys DS Gene software. The results are summarized in Table [2](#Tab2){ref-type="table"}. Analysis of polymorphism of the *P*. *falciparum* isolates showed the presence of mutations in *Pfcrt* and *Pfmdr1* genes linked to resistance to the quinolines and mutation in *Pfdhfr* and *Pfdhps* genes correlated to antifolate/cycloguanil resistance. No mutations associated with artemisinin resistance and atovaquone were detected.Fig. 1Genotyping of *Plasmodium falciparum* isolates responsible for the patient's infection. *M* DNA ladder; *A* sample November 27, 2014; *B* sample January 7, 2015; *C* positive control; *D* negative control Table 2Analysis of the molecular markers of *P. falciparum* linked to drug resistance![](12936_2016_1572_Tab2_HTML.gif){#d30e656}Specific point mutations in *Pfcrt* and *Pfmdr1* gene are linked to quinoline-based antimalarial resistance; *PfK13* is the molecular markers for artemisinin resistance; mutation I258M and Y268F/S in *PfCytB* gene are linked to atovaquone resistance; mutations in *Pfdhfr/Pfdhps* genes are responsible for *P. falciparum* resistance to antifolate-cycloguanil

Conclusion {#Sec3}
==========

This is the first case of failure of DHA-PPQ reported in Europe. The patient returned from Ethiopia, a country where DHA-PPQ failures have not been reported before. In this case, the rapid response to DHA-PPQ and the lack of mutations in the *PfK13* gene suggest the involvement of an artemisinin-sensitive strain. Although it was not possible to analyse a specific molecular marker of resistance to PPQ (a newly identified gene, PFE1085w is presumably associated to resistance to this drug) \[[@CR19]\], the combination of results obtained from molecular and pharmacokinetic analyses and the clinical characteristics support that the strain was resistant to the PPQ component.

In the last 2 years (July 2014 to June 2016) DHA-P was administered to 36 patients attended at the CTD for falciparum malaria, observing no other failure. These data are in agreement with the literature. The efficacy of DHA-PPQ has been found very high, particularly in the African continent. There was a relevant delay between the onset of symptoms and the second diagnosis because the index of suspicion was low due to the negative laboratory tests performed at the 28-day follow-up visit. In consideration of the growing number of cases of resistance to ACT, it is important to consider a possible recrudescence, which can manifest several weeks after treatment.
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